Health

Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

TribeNews
By TribeNews 9 Views Add a Comment
0 Min Read
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC

MedPage Today) — SAN FRANCISCO — The addition of radionuclide therapy with 177Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (CRPC), according…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app